No difference in mortality in COVID-19 'first' and 'second wave': ICMR

Those over 60 years continue to be most at risk from dying.

Updated - April 20, 2021 10:15 am IST

Published - April 19, 2021 04:50 pm IST - NEW DELHI

There was no difference in mortality among COVID-19 patients in the first and second wave, said leading doctors in charge of India’s national COVID management strategy. There was a relative increase in instances of those manifesting shortness of breath as a symptom of the infection but those over 60 — as in the first wave — continued to be most at risk from dying.

A “marginally higher” proportion of patients younger than 20 years were present in the second wave (5.8%) compared to the first (4.2%). In the first wave, 25.5% of the patients were 20-40 years old compared to 23.7% in the ongoing second wave. 

Citing data from a section of hospitalised patients from the first and second wave, Director-General, Indian Council of Medical Research (ICMR) Dr. Balram Bhargava said 47% of symptomatic patients presented ‘shortness of breath’ in the second wave (March-April 2021) compared to 41% in the first wave (Sept.-Nov.’20).

In all other symptoms associated with COVID-19 — ‘fast breathing,’ cough, chills, joint pain, fatigue — there was a greater proportion who manifested these symptoms in the first wave than in the ongoing second wave. A key caveat to the data was that for the first wave analysis, 6,642 patients were analysed, and in the second wave, only 1,405 were analysed.

Of 6, 650 admitted patients from September-November last year, 9.6% succumbed whereas from March-April, 9.7% of a group of 351died from the virus. 

There was no difference in the proportion of patients who required mechanical ventilation in the first and second waves, Dr. Bhargava said.

The second wave — apart from a steep rise in coronavirus cases — has been characterised by unprecedented demand for medical-grade oxygen leading to severe shortages. Dr. Bhargava said the sudden surge may have triggered panic and a demand for more oxygen. “This is data from hospital settings and so we don't yet know what's triggering the demand from outside these settings,” he said at an online meeting.

Dr V.K. Paul, who chairs the empowered group on vaccinations and COVID management (NEGVAC), said there was no difference in mortality, in the first and second wave, in those 40 and under. “There is no overarching extra/ excess risk of younger becoming COVID positive,” he said.

On drug protocol for treatment, Dr. Randeep Guleria stressed that none of the antiviral drugs — Remdesivir, Fapiravir — as well as convalescent plasma had any established benefit in curing the disease. Other medication — the use of the steroids such as dexamethasone, tocilizumab — too had limited use especially in instances of critically ill patients who were experiencing an immune-system over-reaction, called a cytokine storm.

 “Steroids, Tocilizumab, Remdesivir these are to be given, if need be, at the right time. Giving a cocktail of drugs (unsupervised) can be fatal. Remdesivir is useful in moderate illness and to treat a decrease in oxygen saturation but has a limited role. If given too early, dexamethasone (steroid) is harmful and Tocilizumab is only useful during a cytokine storm,” he added.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.